<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962711</url>
  </required_header>
  <id_info>
    <org_study_id>82/21</org_study_id>
    <nct_id>NCT04962711</nct_id>
  </id_info>
  <brief_title>Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)</brief_title>
  <official_title>Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker Heart and Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study in which a process of identifying and reducing heart failure (HF)&#xD;
      risk will be applied to cancer survivors &gt;65 years old with chemotherapy &gt;10 years ago.&#xD;
&#xD;
      The overall goal of this study to identify the feasibility and value of risk-guided cardiac&#xD;
      rehabilitation (exercise, risk factor modification, and behavioural support) as a component&#xD;
      of survivorship care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants enrolled in this study will be randomized to cardio-oncology disease management&#xD;
      plan ( CO-DMP) that involves the use of surveillance imaging to detect subclinical left&#xD;
      ventricular dysfunction (LVD), clinical review to ensure optimal risk factor control and&#xD;
      cardio-protection and exercise/sedentariness intervention. The intervention will be delivered&#xD;
      over a period of 12 months. The outcome from this study will show that subclinical LVD is&#xD;
      more common among long term cancer survivors, and a CO-DMP is feasible in reducing HF risk&#xD;
      factors in this sub group of survivors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization to CO-DMP or usual care</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor will receive study data based on pooled de identified dataset.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in exercise capacity</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Cardio pulmonary fitness (peak oxygen uptake (VO2 peak)) from baseline to follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>proportion of ACEi and beta blocker tablets taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuromuscular strength</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Maximal isometric grip strength (kg) assessed using a digital grip strength dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endurance</measure>
    <time_frame>Over a period of 12 months</time_frame>
    <description>Increase in total exercise duration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart failure intervention ( Cardio-Oncology Disease Management Plan (CO-DMP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimization of pharmacotherapy: Cardioprotection with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol).Participants will be initially treated with ramipril at a dose of 1.25 or 2.5mg (according to baseline systemic arterial pressure), once or twice a day, and gradually up-titrated to 10mg/day, or to the maximal-tolerated dose. In patients receiving at least 2.5mg/day of ramipril, metoprolol will be started at an initial dose of 50 (25mg twice a day) and progressively up-titrated to the maximal dose of 100mg/day. Patients will be reviewed every 2 weeks during the up titration phase.&#xD;
Exercise intervention: Individualized training program provided by an exercise physiologist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Provided by participants' usual healthcare professional(s), guided by a brochure regarding optimal risk factor management addressing hypertension, lipids, alcohol intake and tobacco use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)</intervention_name>
    <description>A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.</description>
    <arm_group_label>Heart failure intervention ( Cardio-Oncology Disease Management Plan (CO-DMP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>provided by participants' usual healthcare professional(s)</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of cancer &gt; 10 years ago&#xD;
&#xD;
          2. Have received potentially toxic chemotherapy Anthracycline (any dose) Trastuzumab&#xD;
             (Herceptin) in breast-cancer with the HER2 mutation OR Tyrosine kinase inhibitors&#xD;
             (e.g. sunitinib) OR Left chest radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ejection fraction at baseline echo &lt;50%&#xD;
&#xD;
          2. Valvular stenosis or regurgitation of &gt;moderate severity&#xD;
&#xD;
          3. History of previous heart failure (baseline New York Heart Association (NYHA)&#xD;
             classification &gt;2)&#xD;
&#xD;
          4. Systolic BP &lt;110 mmHg&#xD;
&#xD;
          5. Pulse &lt;60/minute if not on beta blocker&#xD;
&#xD;
          6. Inability to acquire interpretable images (identified from baseline echo)&#xD;
&#xD;
          7. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors&#xD;
&#xD;
          8. Oncologic (or other) life expectancy &lt;12 months or any other medical condition&#xD;
             (including pregnancy) that results in the belief (deemed by the Chief Investigators)&#xD;
             that it is not appropriate for the patient to participate in this trial&#xD;
&#xD;
          9. Already taking both angiotensin converting enzyme inhibitors/angiotensin receptor&#xD;
             blockers and beta blockers, or intolerance (or allergy) to both.&#xD;
&#xD;
         10. Unable to provide written informed consent to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas H Marwick, MD,PhD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker Heart and Diabetes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anjali Haikerwal, MBBS,MPH,PhD</last_name>
    <phone>+61385321964</phone>
    <email>anjali.haikerwal@baker.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas H Marwick, MD,PhD,MPH</last_name>
    <phone>+61385321550</phone>
    <email>tom.marwick@baker.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baker Heart and Diabetes Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Marwick</last_name>
      <phone>+61385321550</phone>
      <email>tom.marwick@baker.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing based available on application to the study PI</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

